Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial

Journal of Pineal Research

Volumn 35, Issue 1, 2003, Pages 12-15

  Lissoni, Paolo ^a   Chilelli, M ^a   Villa, S ^a   Cerizza, L ^a   Tancini, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Lung cancer; Melatonin; Pineal gland

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; MELATONIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NEUROTOXICITY; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR REGRESSION; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MELATONIN; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0038346728     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-079X.2003.00032.x     Document Type: Article

References (15)

1. VIJAYALAXMI B, THOMAS CR, REITER RJ et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20:2575-2601.
2. LISSONI P. Is there a role for melatonin in supportive care? Supp Care Cancer 2002; 10:110-116.
3. YING SW, NILES LP, CROCKER C. Human malignant melanoma cells express high affinity receptors for melatonin: antiproliferative effects on melatonin and 6-chloromelatonin. Eur J Pharmacol 1993; 246:89-96.
4. CONTI A, MAESTRONI GJM. The clinical immunotherapeutic role of melatonin in oncology. J Pineal Res 1995; 19:103-110.
5. GUERRERO GM, REITER RJ. Melatonin-immune system intereactions. Curr Topics Med Chem 2002; 2:167-180.
6. REITER RJ, TAN DX, MANCHESTER LC et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochem Biophys 2001; 34:232-256.
7. LISSONI P, MANDALÀ M, MANDELLI A et al. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus the pineal oncostatic hormones melatonin and 5-methoxytryptamine in untreatable advanced solid neoplasm patients with very poor clinical status. Int J Immunother 1999; XV:35-38.
8. LISSONI P, PAOLOROSSI F, ARDIZZOIA A et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 1997; 23:15-19.
9. REITER RJ, TAN DX, SAING RM et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharmacy Pharmacol 2002; 54:1299-1321.
10. KATSUMATA N, EGUCHI K, FUKUDA M et al. Serum levels of cytokines in patients with untreated lung cancer. Clin Cancer Res 1996; 2:553-559.
11. CHINERY R, BROCKMAN JA, PEELER MO et al. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF/CIPI via c/EBPbeta. Nat Med 1997; 3:1233-1236.
12. BRZEZINSKY A. melatonin in humans. N Engl J Med 1997; 336:186-195.
13. KLASTERSKY P, SCULIER JP. Chemotherapy of non-small cell lung cancer. Seminars Oncol 1985; 12:36-48.
14. SACCO S, AQUILINI L, GHEZZI P et al. Mechanisms of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro. Eur J Pharmacol 1998; 343:249-255.
15. ATZPODIEN J, KIRCHNER H. Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunohterapy of human neoplasms. Klin Wochenschr 1990; 68:1-11.